Insulin Degludec

Specification

• Cat#: THP-0125
• Product Name: Insulin Degludec
• Description: The product is an ultra-long-acting insulin. Compared to endogenous insulin, this product has an added hexadecanedioic acid to lysine at the B29 position which allows for the formation of multi-hexamers.
• Sequences: >A Chain GIVEQCCTSICSLYQLENYCN >B Chain FVNQHLCGSHLVEALYLVCGERGFFYTPK
• Molecular Weight: 6103.97 Da
• Cas No: 844439-96-9
• Formula: C274H411N65O81S6
• Endotoxin Level: <0.1 EU per 1 μg of the protein by the LAL method
• Biological Activity: 200 U/ml

Pharmaceutical Information

• Pharmaceutical Application: Insulin Degludec
• Applications: The product is indicated to improve glycemic control in adults with diabetes mellitus.
• Examples of Clinical Use: Diabetes mellitus
• Pharmacodynamics: Not Available
• Mechanism of action: Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake and by preventing hepatic glucose production. Compared to endogenous insulin, Insulin Degludec has an added hexadecanedioic acid to lysine at the B29 position which allows for the formation of multi-hexamers in subcutaneous tissues. When injected subcutaneously, these multi-hexamers form a drug depot store that slowly release. As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation
• Affected organisms: Not Available
• Targets: Target 1. Insulin receptor